197 related articles for article (PubMed ID: 29785771)
1. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Storrar NPF; Mathur A; Johnson PRE; Roddie PH
Br J Haematol; 2019 Apr; 185(1):142-144. PubMed ID: 29785771
[No Abstract] [Full Text] [Related]
2. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
[TBL] [Abstract][Full Text] [Related]
3. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Pegourie B; Karlin L; Benboubker L; Orsini-Piocelle F; Tiab M; Auger-Quittet S; Rodon P; Royer B; Leleu X; Bareau B; Cliquennois M; Fuzibet JG; Voog E; Belhadj-Merzoug K; Decaux O; Rey P; Slama B; Leyronnas C; Zarnitsky C; Boyle E; Bosson JL; Pernod G;
Am J Hematol; 2019 Jun; 94(6):635-640. PubMed ID: 30859608
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Bradbury CA; Craig Z; Cook G; Pawlyn C; Cairns DA; Hockaday A; Paterson A; Jenner MW; Jones JR; Drayson MT; Owen RG; Kaiser MF; Gregory WM; Davies FE; Child JA; Morgan GJ; Jackson GH
Blood; 2020 Aug; 136(9):1091-1104. PubMed ID: 32438407
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
6. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
7. The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.
Li A; Wu Q; Warnick G; Li S; Libby EN; Garcia DA; Lyman GH
Ann Hematol; 2020 Jan; 99(1):121-126. PubMed ID: 31773215
[TBL] [Abstract][Full Text] [Related]
8. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Palumbo A; Cavo M; Bringhen S; Zamagni E; Romano A; Patriarca F; Rossi D; Gentilini F; Crippa C; Galli M; Nozzoli C; Ria R; Marasca R; Montefusco V; Baldini L; Elice F; Callea V; Pulini S; Carella AM; Zambello R; Benevolo G; Magarotto V; Tacchetti P; Pescosta N; Cellini C; Polloni C; Evangelista A; Caravita T; Morabito F; Offidani M; Tosi P; Boccadoro M
J Clin Oncol; 2011 Mar; 29(8):986-93. PubMed ID: 21282540
[TBL] [Abstract][Full Text] [Related]
9. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
[TBL] [Abstract][Full Text] [Related]
10. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
[No Abstract] [Full Text] [Related]
11. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Minnema MC; Breitkreutz I; Auwerda JJ; van der Holt B; Cremer FW; van Marion AM; Westveer PH; Sonneveld P; Goldschmidt H; Lokhorst HM
Leukemia; 2004 Dec; 18(12):2044-6. PubMed ID: 15470485
[No Abstract] [Full Text] [Related]
12. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
Lassen MR; Gallus A; Raskob GE; Pineo G; Chen D; Ramirez LM;
N Engl J Med; 2010 Dec; 363(26):2487-98. PubMed ID: 21175312
[TBL] [Abstract][Full Text] [Related]
13. [Effective anticoagulation also in advanced age].
Zimmermann W
MMW Fortschr Med; 2015 Feb; 157(3):72. PubMed ID: 25743684
[No Abstract] [Full Text] [Related]
14. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
15. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
[TBL] [Abstract][Full Text] [Related]
16. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
17. [New oral anticoagulants are as safe in elderly patients as conventional drugs].
Steurer J
Praxis (Bern 1994); 2014 Aug; 103(17):1032. PubMed ID: 25146949
[No Abstract] [Full Text] [Related]
18. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Fenger-Eriksen C; Münster AM; Grove EL
Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulants in hypercoagulable states.
Kunk PR; Brown J; McShane M; Palkimas S; Gail Macik B
J Thromb Thrombolysis; 2017 Jan; 43(1):79-85. PubMed ID: 27632140
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
